Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Roche Holding AG Basel American Depositary Shares
(OP:
RHHBY
)
44.56
USD
+0.61 (+1.39%)
Official Closing Price
Updated: 4:00 PM EST, Jan 15, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Roche Holding AG Basel American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
9
...
40
41
Next >
Genentech’s Novel Anti-TIGIT Tiragolumab Granted FDA Breakthrough Therapy Designation in Combination With Tecentriq for PD-L1-High Non-Small Cell Lung Cancer
January 05, 2021
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that tiragolumab, a novel cancer immunotherapy designed to bind to TIGIT, has been granted Breakthrough Therapy...
From
Business Wire News Releases
Genentech’s Faricimab Meets Primary Endpoint and Shows Strong Durability Across Two Global Phase III Studies for Diabetic Macular Edema, a Leading Cause of Blindness
December 21, 2020
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from two identically designed global Phase III studies, YOSEMITE and RHINE, evaluating its...
From
Business Wire News Releases
FDA Approves Genentech’s Ocrevus (ocrelizumab) Shorter 2-Hour Infusion for Relapsing and Primary Progressive Multiple Sclerosis
December 14, 2020
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a shorter two-hour infusion time for Ocrevus®...
From
Business Wire News Releases
Roche teams up with Diabeloop to advance the management of insulin pump therapy
December 11, 2020
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it is partnering with the French MedTech company Diabeloop to advance the management of insulin pump therapy, creating new opportunities to lower...
From
PR Newswire
Genentech Announces New Data Reinforcing the Long-Term Benefit of Venclexta-Based Combination for People With Relapsed or Refractory Chronic Lymphocytic Leukemia
December 05, 2020
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from the pivotal Phase III MURANO and CLL14 studies support the efficacy of fixed-duration,...
From
Business Wire News Releases
New Pharma Trials Making Big Gains in Fight Against Triple-Negative Breast Cancer (TNBC)
December 02, 2020
Tags
Featured News
From
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
New Pharma Trials Making Big Gains in Fight Against Triple-Negative Breast Cancer (TNBC)
December 02, 2020
FN Media Group Presents USA News Group News Commentary
From
PR Newswire
Genentech Announces FDA Approval of Gavreto (pralsetinib) for People With Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancers
December 01, 2020
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Gavreto™ (pralsetinib) for the treatment of adult and...
From
Business Wire News Releases
Genentech Announces FDA Approval of Xolair (omalizumab) for Adults with Nasal Polyps
December 01, 2020
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License...
From
Business Wire News Releases
Roche receives FDA Emergency Use Authorization for new semi-quantitative test to measure the level of SARS-CoV-2 antibodies
December 01, 2020
- Elecsys® Anti-SARS-CoV-2 S test specifically detects antibodies against the SARS-CoV-2 spike protein
From
PR Newswire
Genentech Announces FDA Approval of Xofluza for the Prevention of Influenza Following Contact With an Infected Person
November 23, 2020
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for...
From
Business Wire News Releases
OneOncology Partners with Genentech to Bring Personalized Cancer Research to Patients at Community Oncology Sites
November 23, 2020
Collaboration Will Advance Comprehensive Genomic Profiling, Clinical Trials and Real-World Data Studies for Cancer Patients
From
PR Newswire
Leading Diagnostics Companies Join Forces to Establish the Access to Comprehensive Genomic Profiling Coalition (ACGP)
November 17, 2020
Consortium aims to make comprehensive genomic profiling accessible to advanced cancer patients in the U.S. to inform medical management and improve patient outcomes.
From
PR Newswire
Spark Therapeutics Expands Visionary Leadership with Appointment of Michael Retterath as Chief Strategy Officer
November 16, 2020
From
GlobeNewswire News Releases
Genentech to Present New Data Across 16 Blood Disorders at the American Society of Hematology 2020 Annual Meeting
November 05, 2020
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data for its approved and investigational medicines will be presented at the all-virtual 62nd American...
From
Business Wire News Releases
Roche receives FDA approval for the cobas EGFR Mutation Test v2 as the first companion diagnostic test for expanded EGFR TKI therapies in patients with non-small cell lung cancer
October 29, 2020
- Lung cancer causes more than 1.7 million deaths worldwide each year, with NSCLC accounting for about 85 percent of all cases[1]
From
PR Newswire
Atea Pharmaceuticals Announces Strategic Collaboration with Roche to Develop and Distribute AT-527 for Patients with COVID-19
October 22, 2020
Roche Obtains Exclusive Right to Develop and Distribute AT-527 Outside the United States
From
GlobeNewswire News Releases
Genentech Announces Full FDA Approval for Venclexta Combinations for Acute Myeloid Leukemia
October 16, 2020
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has granted full approval of Venclexta® (venetoclax) in combination...
From
Business Wire News Releases
Dyno Therapeutics Enters Collaboration and License Agreement With Roche to Develop Next-Generation AAV Gene Therapy Vectors for CNS Diseases and Liver-Directed Therapies
October 14, 2020
Dyno Tx Enters Collaboration and License Agreement with Roche to Develop Next-Gen AAV Gene Therapy Vectors for CNS Diseases, Liver-Directed Therapies
From
Business Wire News Releases
NetworkNewsAudio – 180 Life Sciences Corp. Dedicated to Developing Groundbreaking Anti-Inflammatory Drugs
October 05, 2020
From
InvestorBrandNetwork
Judge Rules Tamiflu-Maker Hoffman-La Roche Must Answer Whistleblower Fraud Claims
October 01, 2020
Lawsuit seeks more than $4B taxpayer recovery for Tamiflu false claims
From
PR Newswire
Solving One of the Largest Drivers of Disease: Inflammation
September 30, 2020
From
InvestorBrandNetwork
Solving One of the Largest Drivers of Disease: Inflammation
September 30, 2020
NetworkNewsWire Editorial Coverage
From
PR Newswire
Genentech Presents New 2-Year Data for Evrysdi (risdiplam) in Infants With Type 1 Spinal Muscular Atrophy (SMA)
September 28, 2020
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new 2-year data from Part 1 of the pivotal FIREFISH study of Evrysdi™ (risdiplam) in infants aged 2-7 months with...
From
Business Wire News Releases
Inflazome Announces Acquisition by Roche
September 21, 2020
Inflazome announced today that it has closed a share purchase agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) in which Inflazome’s shareholders received an upfront payment of €380 million, and are...
From
Business Wire News Releases
Genentech Presents New Data From Multiple Phase III Studies of Tecentriq in Triple-Negative Breast Cancer at ESMO Virtual Congress 2020
September 19, 2020
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that it presented the latest results from three Phase III studies from the Tecentriq® (atezolizumab) clinical...
From
Business Wire News Releases
Genentech’s Phase III EMPACTA Study Showed Actemra Reduced the Likelihood of Needing Mechanical Ventilation in Hospitalized Patients With COVID-19 Associated Pneumonia
September 18, 2020
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III EMPACTA study met its primary endpoint, showing that patients with COVID-19 associated pneumonia...
From
Business Wire News Releases
New Data Further Reinforce Genentech’s Ocrevus (ocrelizumab) as a Highly Effective Treatment for People With Multiple Sclerosis
September 11, 2020
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new data that show Ocrevus® (ocrelizumab) is a highly effective treatment option for people with relapsing-remitting...
From
Business Wire News Releases
New Data Show Genentech’s Enspryng Significantly Reduces Severity and Risk of Relapse in Neuromyelitis Optica Spectrum Disorder
September 10, 2020
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), will present new Enspryng™ (satralizumab-mwge) data on reducing relapse severity in the treatment of neuromyelitis optica spectrum...
From
Business Wire News Releases
Genentech Expands Its Multiple Sclerosis Portfolio With Investigational BTK Inhibitor Fenebrutinib and Initiates Novel Clinical Trials for Ocrevus (ocrelizumab)
September 09, 2020
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the initiation of an innovative Phase III clinical trial program for its investigational medicine fenebrutinib in...
From
Business Wire News Releases
< Previous
1
2
3
4
5
6
7
8
9
...
40
41
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.